Instituto Moléstias Cardiovasculares Tatui
Instituto Moléstias Cardiovasculares Tatui
R. Cel. Aureliano de Camargo, 905 - Centro, Tatuí - SP, 18270-170
Select an option
I am a doctor
I am a sponsor
Our team
Medical staff
Wladmir Saporito
Amanda de Andrade
Ana Julia Estanislau
Katlin Sampaio
Thaís Peretti Pereira
Vinicius Seroque
Milena Freitas
Geovanna Robaiana
Felipe Saporito
Natalia da Silva
Lucas da Silva
Open studies
Obesity
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity - MARITIME-HF - AmgenSee more
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity - MARITIME-CV - AmgenSee more
Cardiovascular disease
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity - MARITIME-CV - AmgenSee more
A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes) - ATTAIN-Outcomes - Eli Lilly and CompanySee more
Heart failure
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity - MARITIME-HF - AmgenSee more
Renal disease
A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes) - ATTAIN-Outcomes - Eli Lilly and CompanySee more
